What is RoosterBio?
Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio is dedicated to accelerating the development of a sustainable Regenerative Medicine industry. The company provides cell manufacturing platform technologies designed to streamline the path from research to commercialization for its clients. RoosterBio's focus on enabling efficient cell production positions it as a key player in the burgeoning field of regenerative therapies, aiming to bring life-changing treatments to market more rapidly.
How much funding has RoosterBio raised?
RoosterBio has raised a total of $35.9M across 6 funding rounds:
Private Equity
$5.2M
Debt
$1.3M
Series A
$6M
Series B
$21.5M
Debt
$1M
Debt
$990K
Private Equity (2016): $5.2M, investors not publicly disclosed
Debt (2017): $1.3M, investors not publicly disclosed
Series A (2017): $6M, investors not publicly disclosed
Series B (2019): $21.5M featuring Bioeconomy Capital, Dynamk Capital, and Vanedge Capital
Debt (2020): $1M backed by PPP
Debt (2021): $990K with participation from PPP
Key Investors in RoosterBio
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy. We expect advances in biology to profoundly improve the human condition and contribute to the global economy. Bioeconomy Capital invests primarily in: (i) technologies that enable biological engineering and production; and (ii) companies that use those technologies to produce goods and services.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies. The firm aims to support innovative companies that are advancing the field of life sciences.
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund based in Vancouver, Canada, focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors. The firm leverages its deep domain expertise, operating experience, and extensive network to support exceptional entrepreneurs in scaling their businesses.
What's next for RoosterBio?
With the recent infusion of major strategic capital, RoosterBio is poised for accelerated growth and enhanced market penetration. The company's focus on scaling its cell manufacturing platform technology suggests a strategic push towards broader industry adoption and the development of new therapeutic applications. This significant backing indicates strong investor confidence in RoosterBio's business model and its potential to lead in the regenerative medicine supply chain, likely leading to expanded partnerships and R&D initiatives.
See full RoosterBio company page
